Dementia Risk Score Developed in U.K. Biobank, Whitehall Cohorts
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 25, 2023 -- A novel risk score can identify individuals at risk for dementia in the United Kingdom, according to a study published online Aug. 24 in BMJ Mental Health.
Malis Anatürk, D.Phil., from University College London, and colleagues developed and validated a novel dementia risk score for a midlife U.K. population using the U.K. Biobank and U.K. Whitehall II study. The U.K. Biobank cohort was divided into a training cohort and test sample (176,611 and 44,151 participants, respectively), and the Whitehall II cohort was used for external validation (2,934 participants). The strongest predictors of incident dementia from 28 candidates were selected, and a risk score was developed using competing risk regression.
The risk score (U.K. Biobank Dementia Risk Score [UKBDRS]) includes age, education, parental history of dementia, material deprivation, a history of diabetes, stroke, depression, hypertension, high cholesterol, household occupancy, and sex. The researchers found that the score had strong discrimination accuracy in the U.K. Biobank test sample and in the Whitehall II cohort (area under the curve, 0.8 and 0.77, respectively). The UKBDRS outperformed other widely used dementia risk scores developed in cohorts in Australia, Finland, and the United Kingdom: the Australian National University Alzheimer's Disease Risk Index, the Cardiovascular Risk Factors, Ageing, and Dementia score, and the Dementia Risk Score.
"While the consistent performance of UKBDRS across these two independent groups boosts our confidence in its viability, we need to evaluate it across more diverse groups of people both within and beyond the UK," coauthor Raihaan Patel, Ph.D., from the University of Oxford in the United Kingdom, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.